Exclusive Summary

• Targets a multi-billion dollar schizophrenia market experiencing explosive demand for long-acting injectables (LAIs).
• Extremely high technical barriers for complex nano-suspension formulation ensure scarce global generic competition, providing a strong blue-ocean moat.
• Matches the 'golden window' of the originator's patent cliff, allowing overseas partners to secure early-mover generic substitution advantages.
• Backed by USP/EP compliant API and superior production cost-efficiency, ensuring highly competitive pricing and massive profit margins for local distributors.